AHP | Syntax PharmaShares AbbVie-Humira Index

Index Description

The Syntax PharmaShares Indices are designed to track in combination the performances of a pharmaceutical company’s share price and the portion of the reported global net sales of that company’s lead drug that are owned and accrued for the benefit of the company. The Syntax PharmaShares AbbVie-Humira Index tracks the combined performance of AbbVie Inc.’s listing of common stock shares (ABBV) on the New York Stock Exchange (NYSE) and the Revenue of the pharmaceutical drug Humira (also known as adalimumab) that are owned and accrued for the benefit of AbbVie Inc.

Index Facts

Number of Constituents 2
Weighting Methodology Equal
Rebalancing Frequency Quarterly
Currency USD
Exchange Symbol/Ticker AHP
Index Inception Date December 28, 2022
Total Return Index Value as of 12/13/2023 3329.39

Index Performance